CHEO Research Institute Logo
Decrease Text SizeIncrease Text SizeFacebookTwitterYoutube

researchers working in a lab

David Dyment Photo of Dr. David Dyment
Investigator, CHEO Research Institute
Physician, Department of Genetics, CHEO
Associate Professor, Faculty of Medicine, University of Ottawa
Research Practice Areas:
Current Research:
Dr. Dyment's research interests include the application of next-generation sequencing technologies in the Neonatal Intensive Care Unit as well as the study of rare, monogenic forms of epilepsy. He also has an active interest in recognizable malformation syndrome such as SHORT syndrome.
Dr. Dyment is a clinical investigator at the CHEO Research Institute and Assistant Professor at the University of Ottawa. He completed his graduate training in the genetics of complex disease at the University of Oxford and medical training in Calgary. His clinical area of interest is neurogenetics and he works as a clinician in the Neurogenetics Program at CHEO. His current research focus is the identification of disease genes involved in rare epilepsies as well as recognizable dysmorphic syndromes. He is the recipient of a CIHR Clinical Investigator award and has a Tier 2 Research Chair in Epilepsy Genetics.
Sample Publications:
Dyment DA, Smith AC, Humphreys P, Schwartzentruber J, Beaulieu CL, FORGE Canada Consortium, Bulman DE, Majewski J, Woulfe J, Michaud J, Boycott KM. "Homozygous nonsense mutation in SYNJ1 associated with intractable epilepsy and tau pathology". Neurobiol Aging. 2015 Feb;36(2):1222.e 1-5. doi:10.1016/j.neurobiolaging.2014.09.005. Epub 2014 Sep 6.

Dyment DA, Tétreault M, Beaulieu CL, Hartley T, Ferreira P, Chardon JW, Marcadier J, Sawyer SL, Mosca SJ, Innes AM, Parboosingh JS, Bulman DE, Schwartzentruber J, Majewski J, Tarnopolsky M, Boycott KM, FORGE Canada Contsortium, Care4Rare Canada. "Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study". Clin Genet, 2015 Jul;88(1):34-40.doi: 10.1111/cge.12464. Epub 2014 Aug 28.

Dyment DA, Sell E, Vanstone MR, Smith AC, Garandeau D, Garcia V, Carpentier S, Le Trionnaire E, Sabourdy F, Beaulieu CL, Schwartzentruber J, McMillan HJ, FORGE Canada Consortium, Majewski J, Bulman DE, Levade T, Boycott KM. "Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy". Clin Genet. 2014 Dec;86(6):558-63. doi: 10.1111/cge.12307. Epub 2013 Nov 21.

Venkateswaran S, Myers KA, Smith AC, Beaulieu CL, Schwartzentruber JA, FORGE Canada Consortium, Majewski J, Bulman D, Boycott KM, Dyment DA. "Whole-exome sequencing in an individual with severe global developmental delay and intractable epilepsy identifies a novel, de novo GRIN2A mutation". Epilepsia. 2014 Jul;55(7):e75-9. doi:10.1111/epi. 12663. Epub 2014 Jun 5. 

Dyment DA, Smith AC, Alcantara D, Schwartzentruber J, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, FORGE Canada Consortium, Majewski J, Bulman DE, O'Driscoll M, Boycott KM, Innes AM. "Mutations in PIK3R1 cause SHORT syndrome". Am J Hum Genet. 2013 Jul 11;93(1):158-66. doi: 10.1016/j.ajhg.2013.06.005. Epub 2013 Jun 27.

Dyment DA, Cader MZ, Chao MJ, Lincoln MR, Morrison KM, Disanto G, Morahan JM, De Luca GC, Sadovnick AD, Lepage P, Montpetit A, Ebers GC, Ramagopalan SV. "Exome sequencing identifies a novel multiple sclerosis susceptibility variant in the TYK2 gene". Neruology. 2012 Jul 31;79(5):406-11. doi: 10.1212/WNL.0b013e3182616fc4. Epub 2012 Jun 27.
Take Action
Quick Links

Our Researchmagnifying glass

abcefg hijklmnopqrst uvwxyz